Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanifibranor dose-ranging proof-of-concept study in adults with NASH
2016-001979-70Phase 2Completed
- Sponsor
- Inventiva
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Inventiva. Primary endpoint: Primary histologic response at week 24. Started Sep 2016; status: completed.
02
Drugs
lanifibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2016-001979-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001979-70.